The NHS has dramatically expanded access to a life-saving cancer therapy, according to NHS England, offering approximately 300 blood cancer patients in England annually a genuine chance at complete remission. Glofitamab (Columvi®), an innovative immunotherapy drug, is now available far earlier in treatment for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a highly aggressive non-Hodgkin lymphoma that has either returned after chemotherapy or failed to respond initially.
Breaking Through Treatment Barriers
This NICE approval represents a transformative shift in lymphoma treatment strategy. Previously, glofitamab remained reserved for patients who had endured two separate treatment regimens—a restriction that meant patients suffered through multiple rounds of grueling chemotherapy before accessing this effective option. Now, patients whose cancer returns after just one course of treatment can access glofitamab immediately, administered every three weeks via intravenous infusion through the NHS Cancer Drugs Fund.
The accessibility improvement cannot be overstated. Sparing patients from unnecessary additional chemotherapy rounds while accelerating access to a more effective therapy represents both medical progress and humanitarian relief.
Remarkable Clinical Results
Clinical trial data demonstrates glofitamab’s extraordinary efficacy. Almost 60% of late-stage DLBCL patients achieved complete remission—a remarkable outcome for advanced disease. The STARGLO trial results proved even more compelling: 54% of patients receiving glofitamab plus chemotherapy survived two years, compared to just 34% receiving standard treatment. This translates to a 42% reduced death risk and 59% reduced disease progression risk.
These statistics represent profound hope for patients facing a disease that annually affects approximately 5,500 people in England, predominantly men over 65 who present with painless gland swelling.
Real Lives Transformed
The statistics gain profound meaning through patient stories. Chris Brown, 70, a retired inland waterways captain from Northumberland, received a stage 4 DLBCL diagnosis, typically a death sentence. After receiving glofitamab, he achieved complete remission by February and has since enjoyed previously unimaginable quality of life: boating with family in Sweden over summer and experiencing what he calls “a new lease of life.”
“I never imagined I’d hear the words ‘complete remission’ after a stage 4 diagnosis,” Brown reflected, expressing gratitude for treatment that once seemed impossible.
Accelerating Innovation Through Fast-Tracking
This approval exemplifies the NHS Cancer Drugs Fund’s transformative impact. Since its 2016 inception, the fund has enabled over 108,000 patients to access cutting-edge cancer therapies faster than traditional approval pathways would permit. Currently assisting approximately 1,000 patients monthly, the fund has fast-tracked over 300 cancer treatment approvals, with 50 new options added within the past 18 months.
Dr. Wendy Osborne, a consultant haematologist treating patients like Chris, emphasized: “I have patients alive now who would have sadly died from high-grade lymphoma if treatments like this had not been fast-tracked.”
Professor Peter Johnson, NHS England’s National Clinical Director for Cancer, underscored the significance: “Antibodies such as glofitamab that harness the power of the immune system are transforming treatment and boosting cure rates.”
For hundreds more patients annually, glofitamab now offers what once seemed impossible—not just survival, but complete remission and reclaimed lives.
